Literature DB >> 25891412

The travails of setting up a living donor liver transplant program: Experience from Pakistan and lessons learned.

Faisal Saud Dar1, Abu Bakar Hafeez Bhatti1, Abdul-Wahab Dogar1, Haseeb Zia1, Sadaf Amin1, Atif Rana2, Rashid Nazer2, Nasir Ayub Khan3, Etizaz-ud-din Khan3, Muhammad Zameer Rajput3,4, Muhammad Salih5, Najmul Hassan Shah5.   

Abstract

Living donor liver transplantation (LDLT) is the only treatment option for patients with end-stage liver disease (ESLD) where cadaveric donors are not available. In developing countries, the inception of LDLT programs remains a challenge. The first successful liver transplantation program in Pakistan started transplantation in 2012. The objective of this study was to report outcomes of 100 LDLT recipients in a developing country and to highlight the challenges encountered by a new LDLT program in a resource-limited setting. We retrospectively reviewed recipients who underwent LDLT between April 2012 and August 2014. Demographics, etiology, graft characteristics, and operative variables were assessed. Outcome was assessed on the basis of morbidity and mortality. All complications of ≥ 3 on the Clavien-Dindo grading system were included as morbidity. Estimated 1-year survival was calculated using Kaplan-Meier curves, and a Log-rank test was used to determine the significance. Outcomes between the first 50 LDLTs (group 1) and latter 50 LDLTs (group 2) were also compared. Median age was 46.5 (0.5-72) years, whereas the median MELD score was 15.5 (7-37). The male to female ratio was 4:1. ESLD secondary to hepatitis C virus was the most common indication (73% patients). There were 52 (52%) significant (≥ grade 3) complications. The most common morbidities were bile leaks in 9 (9%) and biliary strictures in 14 (14%) patients. Overall mortality in patients who underwent LDLT for ESLD was 10.6%. Estimated 1-year survival was 87%. Patients who underwent transplantation in the latter period had a significantly lower overall complication rate (36% versus 68%; P = 0.01). Comparable outcomes can be achieved in a new LDLT program in a developing country. Outcomes improve as experience increases.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25891412     DOI: 10.1002/lt.24151

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Living Donor Liver Transplantation in South Asia: Single Center Experience on Intermediate-Term Outcomes.

Authors:  Faisal S Dar; Abu Bakar H Bhatti; Ammal I Qureshi; Nusrat Y Khan; Zahaan Eswani; Haseeb H Zia; Eitzaz U Khan; Nasir A Khan; Atif Rana; Najmul H Shah; Mohammad Salih; Rashid Nazer
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

2.  Serious fungal infections in Pakistan.

Authors:  K Jabeen; J Farooqi; S Mirza; D Denning; A Zafar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-04       Impact factor: 3.267

3.  Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients.

Authors:  Fahad Azam; Moosa Khan; Tanwir Khaliq; Abu Bakar Hafeez Bhatti
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088

4.  Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients.

Authors:  Fahad Azam; Moosa Khan; Abida Shaheen; AbuBakar Hafeez Bhatti
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

5.  Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience from Pakistan.

Authors:  Abu Bakar H Bhatti; Faisal S Dar; Ammal I Qureshi; Nusrat Y Khan; Haseeb H Zia; Siraj Haider; Najmul H Shah; Atif Rana
Journal:  J Clin Exp Hepatol       Date:  2019-05-01

6.  Living Donor Liver Transplantation for Acute on Chronic Liver Failure Based on EASL-CLIF Diagnostic Criteria.

Authors:  Abu Bakar H Bhatti; Faisal S Dar; Muhammad O Butt; Eraj Sahaab; Mohammad Salih; Najmul H Shah; Nusrat Y Khan; Haseeb H Zia; Eitzaz U Khan; Nasir A Khan
Journal:  J Clin Exp Hepatol       Date:  2017-11-24

Review 7.  Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective.

Authors:  Abu Bakar Hafeez Bhatti; Faisal Saud Dar; Anum Waheed; Kashif Shafique; Faisal Sultan; Najmul Hassan Shah
Journal:  Gastroenterol Res Pract       Date:  2016-02-03       Impact factor: 2.260

8.  Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.

Authors:  Abu Bakar Hafeez Bhatti; Wajih Naqvi; Nusrat Yar Khan; Haseeb Haider Zia; Faisal Saud Dar; Zahid Amin Khan; Atif Rana
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-12       Impact factor: 4.553

9.  Living Donor Liver Transplantation During the COVID-19 Pandemic: an Evolving Challenge.

Authors:  Abu Bakar Hafeez Bhatti; Malka Nazish; Nusrat Yar Khan; Fazal Manan; Haseeb Haider Zia; Abid Ilyas; Wasib Ishtiaq; Nasir Ayub Khan
Journal:  J Gastrointest Surg       Date:  2021-06-15       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.